Search results
Results from the WOW.Com Content Network
Basal insulin is provided as a once or twice daily injection of dose of a long-acting insulin. In an MDI regimen, long-acting insulins are preferred for basal use. An older insulin used for this purpose is ultralente, and beef ultralente in particular was considered for decades to be the gold standard of basal insulin.
Prandial insulin, also called mealtime or bolus insulin, is designed as a bolus dose of insulin prior to a meal to regulate the spike in blood glucose that occurs following a meal. The dose of prandial insulin may be static, or may be calculated by the patient using either their current blood sugar, planned carbohydrate intake, or both.
twice a day / twice daily bis in die gtt., gtts drop(s) gutta(e) h., h hour: hora: qhs, h.s., hs at bedtime or half strength quaque hora somni ii two tablets duos doses iii three tablets trēs doses n.p.o., npo, NPO nothing by mouth / not by oral administration: nil per os o.d., od, OD right eye. once a day (United Kingdom) oculus dexter omne ...
twice daily bib. bibe: drink bis bis: twice b.i.d., b.d. bis in die: twice daily AMA style avoids use of this abbreviation (spell out "twice a day") bis ind. bis indies: twice a day bis in 7 d. bis in septem diebus: twice a week BM bowel movement: commonly used in the United Kingdom when discussing blood sugar.
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. [7] It is injected just under the skin . [ 7 ]
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. [1] [2] It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. [1]
Insulin glargine/lixisenatide is approved as a prescription for adults with type 2 diabetes mellitus poorly controlled by lixisenatide or basal insulin alone. [6] According to the American Diabetes Association, combination treatment of a GLP-1 receptor agonist with basal insulin should occur after HbA1C levels remain above target (7% for most type 2 people with diabetes) following use of basal ...
[5] So, the cost per DDD of an extended-release tablet taken once a day compared with a standard tablet taken twice a day, may indicate the extended-release tablet costs much more to treat the same condition. In contrast, using DDD to compare the cost of different drugs or drug groups is "usually not valid" according to the WHO.